Bionova Capital
Also known as Bionova Capital SCR, SA, Hovione Capital
Lisbon healthcare VC company (SCR) founded 2015 as Hovione Capital; invested in European life-science startups 2015–2024. Its site says it stopped new investments and only manages its portfolio.
- HEADQUARTERS
- Lisbon, Portugal
- FOUNDED
- 2015
- AUM
- —
- OUTSIDE CAPITAL
- —
- TEAM LISTED
- 3 people
Focus
- STAGES
- —
- ASSET MIX
- Venture capital
- GEOGRAPHY
- Europe
Overview
Bionova Capital SCR, SA is a Lisbon healthcare venture capital company founded in 2015 as Hovione Capital by the shareholders of pharmaceutical company Hovione; it took its current name in February 2021 when it added therapeutics to its medtech and digital-health focus. From 2015 to 2024 it invested in seven early-stage life-science companies across Europe and reports two profitable exits, Anybrain and CellmAbs, whose antibody candidate BioNTech acquired in January 2024. Its team formed Biovance Capital Partners in 2023 and moved there fully in 2024 with Biovance Capital Fund I (up to €60M), and Bionova has stopped making new investments. Active holdings are Adapttech, Delox, SolasCure and Vaxdyn.
Investment thesis
Early-stage life-science companies across Europe developing therapeutics, medtech and digital-health products, with hands-on support from a healthcare-specialised team.
PORTFOLIO (6)
People
Links
Frequently asked questions
Bionova Capital is a VC fund based in Lisbon, Portugal, founded in 2015.
Yes. Bionova Capital invests its own capital in private companies.
Bionova Capital invests in Biotech & Life Sciences and HealthTech.
Key people at Bionova Capital include Ricardo Perdigão Henriques (CEO (former team, 2019–2024)), Peter Villax (Chairman (former team, 2019–2024)) and João Botelho (Finance Director (former team, 2019–2024)).
Bionova Capital's investments include CellmAbs, Anybrain, Adapttech, Vaxdyn, Delox and SolasCure.
The most recent publicly reported investment by Bionova Capital is Delox, announced in May 2022.